Insulin Resistance Increases Risk for Alzheimer's Disease
Insulin resistance, broadly defined as reduced tissue responsiveness to the action of insulin, is common in people who are obese, prediabetic or have Type 2 diabetes. Insulin has been increasingly recognised as playing an important role in the brain, according to the study background.
Barbara B. Bendlin, PhD, of the University of Wisconsin School of Medicine and Public Health, and colleagues examined 150 cognitively normal, late middle-age adults (average age nearly 61) from the Wisconsin Registry for Alzheimer’s Prevention (WRAP) study, a general community sample enriched for AD parental history. The subjects underwent cognitive testing, a fasting blood draw and fludeoxyglucose F 18-labelled positron emission tomography (PET) of the brain.
Of the 150 participants, 108 (72 percent) were women, 103 (68.7 percent) had a parental history of AD, 61 (40.7 percent) had an APOE ε4 allele and seven (4.7 percent) had type 2 diabetes.
Dr. Bendlin's team found that insulin resistance was associated with lower global glucose metabolism and lower regional glucose metabolism across large portions of the brain in the frontal, lateral, parietal, lateral temporal and medial temporal lobes. Lower glucose metabolism in the left medial temporal lobe was related to worse performance in immediate memory, according to researchers.
The study is the first to look at insulin resistance in late middle-aged people, identify a pattern of decreased blood sugar use related to AD and link that to memory decline.
“The prevalence of AD continues to grow, and midlife may be a critical period for initiating treatments aimed at preventing or delaying the onset of AD. Accumulating evidence suggests that treatments targeting mechanisms involved in insulin signalling may affect central glucose metabolism and should be investigated in the context of presymptomatic AD,” the authors conclude.
Image credit: Flickr.com
Published on : Tue, 28 Jul 2015
Print as PDF
Sectra provides a complete solution for primary diagnostics in pathology. The solution includes archiving and storage solutions together with high-end review workstations. It allows pathologists to make their diagnoses and reports with higher precision...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
The new 3Dimensions™ Mammography System matches the unrivaled performance of our 3D Mammography™ exam, which is more accurate than conventional 2D mammograms, detecting 20-65% more invasive breast cancers.Breakthrough improvements transform the patient...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new wide-angle...